Advertisement

Topics

ASIT biotech Presented the Immunogenicity Data of the gp-ASIT+™ Phase III Clinical Study for the Treatment of Grass Pollen Rhinitis at EAACI 2017

01:01 EDT 3 Jul 2017 | FinanzNachrichten

Striking immunogenicity results in a subset of grass pollen allergic patients reveal, for the first time ever, the induction by gp-ASIT+™ of a sound and groundbreaking immunoregulatory mechanism o...

Original Article: ASIT biotech Presented the Immunogenicity Data of the gp-ASIT+™ Phase III Clinical Study for the Treatment of Grass Pollen Rhinitis at EAACI 2017

NEXT ARTICLE

More From BioPortfolio on "ASIT biotech Presented the Immunogenicity Data of the gp-ASIT+™ Phase III Clinical Study for the Treatment of Grass Pollen Rhinitis at EAACI 2017"

Advertisement
Quick Search
Advertisement
Advertisement